TAZAROTENE
Clinical safety rating: avoid
Contraindicated (not allowed)
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
| Metabolism | Tazarotene is rapidly metabolized by esterases to its active metabolite, tazarotenic acid. Further metabolism occurs via hydroxylation, oxidation, and conjugation (glucuronidation), primarily in the liver. |
| Excretion | Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine. |
| Half-life | Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days. |
| Protein binding | Tazarotenic acid is >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution for tazarotenic acid is approximately 2.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: systemic absorption is minimal (<1% of applied dose under normal conditions); oral not formulated for systemic use. |
| Onset of Action | Topical: improvement in acne within 4 weeks; for psoriasis, noticeable reduction in scaling and erythema within 2–4 weeks. |
| Duration of Action | Topical: therapeutic effects persist for several weeks after cessation; in psoriasis, remission may last up to 3 months. |
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for topical use. Systemic absorption is minimal; no specific GFR-based guidelines available. |
| Liver impairment | No dose adjustment required for topical use. Systemic absorption is minimal; no specific Child-Pugh based guidelines available. |
| Pediatric use | Approved for acne vulgaris in patients ≥12 years: apply a pea-sized amount of 0.1% cream or 0.045% or 0.1% lotion once daily. For plaque psoriasis, safety and efficacy not established in pediatric patients <18 years. |
| Geriatric use | No specific dose adjustments; use caution due to potential increased skin fragility and reduced renal/hepatic function. Monitor for local adverse reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Highly teratogenic females must use effective contraception.
| Breastfeeding | Unknown if tazarotene is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during use and for 2 weeks after last application. |
| Teratogenic Risk | Tazarotene is a topical retinoid contraindicated in pregnancy (Category X). Systemic absorption is minimal (~1-6%) but teratogenic risk exists; fetal exposure can cause retinoid-like malformations including CNS, cardiovascular, and craniofacial defects. Avoid in pregnant women or those planning pregnancy. If pregnancy occurs during use, immediate discontinuation is advised. |
■ FDA Black Box Warning
Tazarotene is contraindicated in women who are or may become pregnant. Exposure during pregnancy is associated with a high risk of severe birth defects, similar to other retinoids.
| Common Effects | Nausea Vomiting Diarrhea Rash Allergic reaction |
| Serious Effects |
["Pregnancy or women planning pregnancy.","Hypersensitivity to tazarotene or any component of the formulation.","Use in patients with severe eczema or sunburned skin."]
| Precautions | ["Avoid use during pregnancy; effective contraception required for women of childbearing potential.","Photosensitivity: advise sun protection and avoid sunlamps.","Local skin reactions: burning, stinging, erythema, peeling, pruritus; reduce frequency or concentration if severe.","Avoid application on eczematous or sunburned skin.","Potential for increased absorption with concurrent dermal irritation or use on large body surface areas.","Not recommended for use on intertriginous areas."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of teratogenicity if inadvertent pregnancy exposure occurs. No specific monitoring required beyond standard pregnancy surveillance. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment at systemic exposures comparable to human topical use. |